PMID- 8436212
OWN - NLM
STAT- MEDLINE
DCOM- 19930323
LR  - 20190909
IS  - 0902-4441 (Print)
IS  - 0902-4441 (Linking)
VI  - 50
IP  - 1
DP  - 1993 Jan
TI  - Comparative pharmacokinetics of single-dose administration of mammalian and 
      bacterially-derived recombinant human granulocyte-macrophage colony-stimulating 
      factor.
PG  - 32-6
AB  - Pharmacokinetics of recombinant human non-glycosylated bacterially-synthesized 
      (E. coli) granulocyte-macrophage colony-stimulating factor (GM-CSF) were studied 
      following single intravenous (i.v.) and subcutaneous (s.c.) bolus injection, and 
      compared to equivalent doses of glycosylated mammalian-derived CHO-GM-CSF. Each 
      route of administration gave a different GM-CSF concentration-time profile. The 
      highest peak serum concentrations (Cmax) were observed following i.v. bolus 
      injection. After i.v. administration, a two-phase decline in concentration was 
      noted for both types of GM-CSF with a significantly shorter t1/2 alpha of 7.8 
      minutes for the E. coli GM-CSF versus 20.0 min for the CHO-GM-CSF, while no 
      significant difference was observed for the terminal phase. Following s.c. 
      administration of equivalent doses, a higher peak serum concentration was 
      observed in the E. coli-treated patients and, again, a faster elimination where 
      pretreatment serum levels were reached after 16-20 h, versus more than 48 h after 
      administration of CHO-GM-CSF. Although the non-glycosylated E. coli GM-CSF thus 
      seems to undergo a faster elimination that the glycosylated CHO-GM-CSF no 
      significant difference could be demonstrated in the in vivo effect of 
      corresponding doses of the two compounds with respect to stimulation of 
      granulopoiesis--with reservation for small patient numbers and a large individual 
      variations in response.
FAU - Hovgaard, D
AU  - Hovgaard D
AD  - Department of Hematology, Rigshospitalet, Copenhagen, Denmark.
FAU - Mortensen, B T
AU  - Mortensen BT
FAU - Schifter, S
AU  - Schifter S
FAU - Nissen, N I
AU  - Nissen NI
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Eur J Haematol
JT  - European journal of haematology
JID - 8703985
RN  - 0 (Recombinant Proteins)
RN  - 83869-56-1 (Granulocyte-Macrophage Colony-Stimulating Factor)
SB  - IM
MH  - Animals
MH  - CHO Cells/metabolism
MH  - Cricetinae
MH  - Escherichia coli/metabolism
MH  - Glycosylation
MH  - Granulocyte-Macrophage Colony-Stimulating Factor/administration & 
      dosage/*pharmacokinetics/therapeutic use
MH  - Half-Life
MH  - Humans
MH  - Injections, Intravenous
MH  - Injections, Subcutaneous
MH  - Kinetics
MH  - Leukocyte Count
MH  - Lymphoma/*blood/drug therapy
MH  - Neutrophils/drug effects
MH  - Recombinant Proteins/administration & dosage/pharmacokinetics/therapeutic use
EDAT- 1993/01/01 00:00
MHDA- 1993/01/01 00:01
CRDT- 1993/01/01 00:00
PHST- 1993/01/01 00:00 [pubmed]
PHST- 1993/01/01 00:01 [medline]
PHST- 1993/01/01 00:00 [entrez]
AID - 10.1111/j.1600-0609.1993.tb00071.x [doi]
PST - ppublish
SO  - Eur J Haematol. 1993 Jan;50(1):32-6. doi: 10.1111/j.1600-0609.1993.tb00071.x.